3. A drug cross skin management system for cross skin drug management of a third class of amines (such as rivastigomina, styrene or rotigotin) drug, including a polymer matrix, including a free radical form of a drug and at least one compound containing a carboxyl group. In some forms of implementation,These systems include a flow control membrane and a bonding surface that contacts the skin separated from the polymer matrix. Claim 1: a cross skin management system for a drug, comprising a polymer matrix, wherein a drug containing a tertiary amine and at least a free radical form of a compound containing a carboxyl group are included,In this case, the relative number of free radicals and compounds in a carbon box group makes more than 50% of the free radicals associated with a carbon box group to form salt. Claim 10: a drug symmetry management system implemented in accordance with any one of the requirements of 1-7, wherein at least one compound containing a carbon aggregate is a polyacyl carboxyl acid.Among the polyurethanes, they are selected from the copolymers based on methylmethylmethylmethylmethylmethylmethacrylic acid and methacrylic acid, linear polymers and ethylene polymers containing anthrax acid. Cellulose polymers containing a group of anthrax or starch contain a group of anthrax. Claim 24: a drug for skin management system in accordance with any one of claims 1-7, wherein the polymer matrix comprises polymers selected from a group consisting of acrylic polymer, silicon polymer and polyisobutyl polymer,Styrene isopropene copolymer and two or more mixtures thereof. 150. Claim 25: the drug referred to in claim 7 crosses the skin management system, and the membrane controlling the flow includes a polymer selected from the polyethylene, polyene and / or vinyl acetate polymer group. Claim 26: a drug cross skin management system consistent with claim 7, wherein the surface adhesive comprises a polymer, selected from the propylene polymer and silicon polymer g
